Bliss GVS Pharma Ltd. (BLISSGVS-BE): Bliss GVS Pharma 52 Week High Streak: Fourth Straight Session

Bliss GVS Pharma Ltd. has now set a fresh 52-week high for its fourth consecutive session, with the streak up 8.48% from the start of the run. The latest peak stands at Rs 668.7, matching the current price, while the article timestamp shows the stock is being tracked in real time. The latest Univest figures confirm the repeated-high pattern, but they do not establish a company-specific catalyst for the continued move.

As of 04 September 2026 at 11:48 AM IST, the stock was trading above the previous close of Rs 636.9, after opening at Rs 647.9 and touching a low of Rs 611.1. Turnover stood at Rs 0.35 crore and market capitalisation at Rs 6,897.26 crore. For readers, the key difference versus a one-day breakout is the persistence of the pattern across multiple sessions, which keeps the stock in the spotlight as a repeated one-year high name.

Bliss GVS Pharma 52 Week High Streak: Consecutive High Analysis

Metric	Value
Current Price	Rs 668.7
Previous Close	Rs 636.9
Today's Move	+Rs 31.8 (+4.99%)
Open	Rs 647.9
High	Rs 668.7
Low	Rs 611.1
Turnover	Rs 0.35 crore
Market Capitalisation	Rs 6,897.26 crore

Bliss GVS Pharma Ltd. (BLISSGVS-BE) traded at Rs 668.7 versus the previous close of Rs 636.9, a rise of 4.99%. The stock opened at Rs 647.9, reached a high of Rs 668.7 and touched a low of Rs 611.1.

Bliss GVS Pharma share price today moved to Rs 668.7, which is Rs 31.8 or 4.99% above the previous close of Rs 636.9. The stock opened at Rs 647.9, moved between Rs 611.1 and Rs 668.7, and last traded at the day’s high, showing that the current reading sits at the top of the day’s range. Turnover was Rs 0.35 crore, while market capitalisation stood at Rs 6,897.26 crore.

This session matters because it extends the already active 52-week high pattern rather than creating a one-off spike. The stock price update also places Bliss GVS Pharma NSE and BSE investors on watch for how long the repeated high structure can persist. For stock news tracking, the most relevant point is that the latest price equals the fresh 52-week high and adds another day to the streak.

Bliss GVS Pharma 52 Week High Streak: Consecutive High Analysis

The most useful comparison is against the prior 52-week high, which is not separately listed here, so the key verified point is the sequence itself rather than a day-by-day ladder of peaks. For readers searching Bliss GVS Pharma New One Year High or Bliss GVS Pharma Back to Back 52 Week Highs, the important fact is that the stock has repeatedly reset its 52-week peak across consecutive sessions. The data confirms the pattern, but it does not identify a company-specific reason for why the sequence is continuing.

What the Repeated 52-Week Highs Show

The repeated 52-week highs show that Bliss GVS Pharma is not being judged only on one trading day’s move. A four-session streak tells readers that the stock has kept registering a fresh one-year high on each of those sessions, which is the core distinction behind this extended streak article. The cumulative gain also gives a fuller read than the day change alone.

For investors tracking stocks hitting 52 week highs, this pattern is useful because it keeps the company in the “Stocks At One Year High Today” and “Stocks In News Today” conversation for longer. It also means that the latest market update is better viewed as a continuing trend in the share price rather than a one-off intraday event. The latest Univest data confirms the repeated-high structure, while the reason for the move remains unconfirmed in the figures provided.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 6,897.26 crore
P/E Ratio	49.7x
P/B Ratio	5.49x
ROE	12.11%
ROCE	17.4%
EPS	Rs 12.81
Book Value Per Share	Rs 116
Dividend Yield	0.24%

Bliss GVS Pharma Ltd. (BLISSGVS-BE) fundamental metrics show P/E 49.7x, P/B 5.49x, ROE 12.11%, ROCE 17.4%. These figures provide context only and are not a buy or sell signal.

Bliss GVS Pharma Ltd. has a market capitalisation of Rs 6897.26 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 49.7x, P/B at 5.49x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 12.11% and ROCE of 17.4%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 12.81, book value per share of Rs 116, dividend yield of 0.24%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 32.28x, median ROE of 11.78%, median ROCE of 13.65%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	49.7x
Benchmark Median P/E	32.28x
Benchmark Average P/E	48.82x
Benchmark P/E Range	3.32x to 645.91x
Company P/B Ratio	5.49x
Benchmark Median P/B	2.85x
Company ROE	12.11%
Benchmark Median ROE	11.78%
Company ROCE	17.4%
Benchmark Median ROCE	13.65%
Company Market Capitalisation	Rs 6,897.26 crore
Benchmark Median Market Cap	Rs 723.58 crore

Bliss GVS Pharma Ltd. (BLISSGVS-BE) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a P/E ratio of 49.7x, which is above the benchmark median of 32.28x, a difference of +53.97%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a ROE of 12.11%, which is above the benchmark median of 11.78%, a difference of +2.8%. Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a ROCE of 17.4%, which is above the benchmark median of 13.65%, a difference of +27.47%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Supriya Lifescience Ltd.	SUPRIYA	6,781.48	34.19	5.55	20.74	27.63
SYMBIOTEC PHARMALAB LTD	SYMBIOTEC	7,018.05	62.96	4.66	11.22	12.41
SENORES PHARMACEUTICALS L	SENORES	6,678.69	52.2	6.84	11.78	11.94
Sanofi India Ltd.	SANOFI	7,299.9	22.76	8.92	44.5	55.46
Innova Captab Ltd.	INNOVACAP	6,373.43	41.16	5.67	13.75	15.04

Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a P/E ratio of 49.7x compared with the displayed peer median of 41.16x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 12.11% compares with a peer median of 13.75% across the companies shown in the table. ROCE stood at 17.4% versus the displayed peer median of 15.04%, providing a capital-efficiency comparison. Bliss GVS Pharma Ltd. (BLISSGVS-BE) has a market capitalisation of Rs 6,897.26 crore. Among the 5 peers shown, 2 have a larger market capitalisation.

Why Investors Are Watching Bliss GVS Pharma

• Bliss GVS Pharma 52 Week High Streak has reached a fourth consecutive session.
• The stock is trading at Rs 668.7, which is also the latest 52-week high.
• The cumulative move across the streak stands at 8.48%.
• Market capitalisation is Rs 6,897.26 crore, keeping the stock in a closely watched size band within healthcare.
• The valuation sits above the peer median on both P/E and P/B, which keeps Bliss GVS Pharma stock analysis in focus.

About Bliss GVS Pharma Ltd.

Bliss GVS Pharma Ltd. is an Indian pharmaceutical company listed on NSE and BSE under the symbol BLISSGVS-BE. It operates in the Pharmaceuticals & Drugs industry within the Healthcare sector. For readers following Bliss GVS Pharma share price today, the company is currently being watched because its share price has stayed near a fresh one-year peak across multiple sessions.

The company’s reported market capitalisation is Rs 6,897.26 crore. On the latest snapshot, the stock combines a premium valuation with mid-teen return metrics, which is why the market update remains relevant for those tracking its stock performance, market capitalisation and broader company news.

Track Bliss GVS Pharma on Univest

Follow Bliss GVS Pharma share price update, stock news and company financials on Univest for the latest market read. The stock page can help readers monitor the next price point, the continuing 52-week high streak and fresh market update as it develops during the trading day.

Frequently Asked Questions

Why is Bliss GVS Pharma still hitting 52-week highs?

Ans. The latest Univest figures confirm that Bliss GVS Pharma has set a fresh 52-week high for a fourth consecutive session. However, the figures do not establish a company-specific catalyst for the repeated move, so the pattern should be read as a price fact rather than.

How many sessions has Bliss GVS Pharma been making new one-year highs?

Ans. Bliss GVS Pharma has now made a fresh 52-week high for four consecutive sessions. That makes this a repeated high streak rather than a single-day breakout, and the cumulative move across the sequence is 8.48%.

What is the latest price in the Bliss GVS Pharma 52 Week High Streak?

Ans. The latest price is Rs 668.7, which is also the current 52-week high in this streak. The stock was last traded at that level as of 04 September 2026 at 11:48 AM IST.

How did Bliss GVS Pharma move in the latest trading update?

Ans. Bliss GVS Pharma was up Rs 31.8, or 4.99%, versus the previous close of Rs 636.9. It opened at Rs 647.9 and moved between Rs 611.1 and Rs 668.7 during the period tracked.

Is Bliss GVS Pharma expensive compared with peers?

Ans. Bliss GVS Pharma trades at a P/E of 49.7 and a P/B of 5.49, both above the industry median in the healthcare benchmark set. That places the stock at a premium to many peers on valuation metrics.

What do the company’s return ratios show?

Ans. The latest figures show ROE of 12.11% and ROCE of 17.4%. Both are useful for comparing operating efficiency and returns against sector and peer benchmarks, especially when paired with valuation ratios.

What should investors monitor next in Bliss GVS Pharma stock news?

Ans. Investors should track whether the repeated 52-week high pattern continues, how the share price behaves around Rs 668.7, and whether the next market update brings new information that explains the streak. The latest figures confirm the pattern but not the cause.

Which sector and industry does Bliss GVS Pharma belong to?

Ans. Bliss GVS Pharma belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. That context matters because valuation and return metrics are often compared closely within the same industry set.

Track Bliss GVS Pharma Ltd. (BLISSGVS-BE) Share Price on Univest

Use Bliss GVS Pharma Ltd. (BLISSGVS-BE) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.